Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. It’s also initiating phase 2a clinical trial into conditions such as eating disorders and fibromyalgia. 10 Psychedelic Companies To Watch In 2022. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JANUARY 13, 2022

Happy 2022! In The Weeds welcomes the new year, as well as a number of new cannabis laws and policies taking effect around the country in 2022. 1, Philadelphia employers cannot require applicants to be drug-tested for marijuana as a condition of employment. McGuireWoods LLP. Newsworthy Highlights. Montana: As of Jan.

Dispensary 52

Dispensary Law Concentrates Patients 52

Cannabis Law Report

APRIL 14, 2022

Local governments may also impose zoning conditions on cannabis facilities, including but not limited to buffer zones, density conditions, hours of operation, odor control requirements, necessary operating permits, and storefront characteristics. pursuant to Drug Enforcement Agency (DEA) or state-level programs).

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA). 2] David E.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Canna Law Blog

MARCH 21, 2022

To impose a hemp moratorium, a county must simply declare a state of emergency related to cannabis and notify the Oregon Department of Agriculture ( ODA ) of the declaration and request that the ODA deny issuance of grower licenses in order to alleviate the conditions giving rise to the declaration. In 2020, the U.S.

Hemp 75

Hemp DEA Conditions Agriculture 75

Canna Law Blog

NOVEMBER 21, 2021

Earlier this year, we wrote about how MAPS was progressing through the Phase III study process and was targeting FDA approval in 2022 and commercialization in 2023 — if these targets are met, they would be on par with Oregon’s legal psilocybin licensing program.

Decriminalization 84

Decriminalization DEA Conditions Food 84

Cannabis Law Report

NOVEMBER 20, 2021

Drug Enforcement Administration (DEA), the Alabama Prescription Drug Monitoring Program maintained by Alabama Department of Public Health, and the Alabama Medical Cannabis Patient Registry System maintained by the Alabama Medical Cannabis Commission. Obtaining this permit requires the physician to: complete an application. 31 each year.

Patients 52

Patients DEA Dispensary Conditions 52

Cannabis Law Report

MARCH 3, 2022

— Cannabis & Tech Today (@cannatechtoday) February 24, 2022. I’ve worked on this for so long that I know not only can it work, sometimes it’s the only thing that works for some of these conditions.”. “We link] #news #cannatechtoday #breaking #thc #florida #orlando #clinton #cbd #pain.

Media 52

Media CBD Events THC 52

Veriheal

DECEMBER 27, 2022

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. BUFFALO, N.Y. , Aug. Tweet this. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Canna Law Blog

JULY 2, 2022

On June 14, 2022, Harris Bricken attorneys Fred Rocafort, Jihee Ahn, Paul Coble, and Vincent Silwoski presented a webinar entitled Protecting, Monetizing and Enforcing Cannabis Intellectual Property. The DEA recently stated that cannabis seeds containing less than 0.3% delta-9-THC). the red and blue portions).

Extraction 69

Extraction Strains Conditions Cannabis 69

Cannabis Law Report

MAY 31, 2022

The only opportunity to currently participate would be through an active clinical trial or via an argument under the Right to Try Act of 2018 (an act which provides a pathway for patients with life-threatening diseases or conditions to access unapproved treatments). 2022 Active FDA Clinical Trials and State-Regulated Systems.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. Practicing veterinarians face a barrage of questions from pet owners about the use of CBD animal products for conditions ranging from arthritis to anxiety. Christine Lawson.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. April 5, 2022. The chemical purity of the final product exceeded 99.9%

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JULY 28, 2021

The DEA, which enforces the CSA, has indicated that it may consider delta-8 derived from hemp to be a “synthetically derived tetrahydrocannabinol” which still belongs on Schedule I of the CSA. percent on a dry weight basis.” ” See 7 U.S.C. See 2021 NY S.B. 854, §§90-111.

THC 105

THC Hemp CBD Cannabinoids 105

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

SEPTEMBER 12, 2022

Government Agencies seek funding to research cannabinoids as treatments for various conditions: [link]. Louisiana allows doctors to decide conditions: [link]. DEA grants research license for psychedelics and major depression first human trial: [link]. Cannabinoids. Delta 8 now legal in Kentucky: [link].

DEA 98

DEA Dispensary Hemp Therapy 98

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. state and federal law to U.S.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

NOVEMBER 17, 2022

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp.

Research and Development 52

Research and Development Pharmaceutical DEA Cannabinoids 52

Cannabis Law Report

JULY 27, 2022

July 27, 2022. As of July 2022, 38 states have legalized the medical use of cannabis to differing degrees. Each jurisdiction has its own criteria regarding what conditions cannabis can be prescribed for, in what amounts, and the process for issuing medical marijuana licenses. By Raymond Lahoud.

Marijuana 52

Marijuana DEA State Laws Policy 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Transaction expected to close in June 2022 , following anticipated shareholder approval. The offer price represents a premium of 51% to Novamind’s 20-day volume-weighted average price (“VWAP”) on the Canadian Securities Exchange (the “CSE”) as of April 8, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

FEBRUARY 16, 2022

So, I’m legitimately, I’m a strength conditioning coach. billion made in two years, just two years from January 2020 to January 2022. And proficiency testing right now, because of the DEA is very limited in what can get sent out. So yeah, cortisol, stress, this all connects for me, Steve.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others.

Therapy 78

Therapy Access Blood Pressure Treatment 78

SpeedWeed

APRIL 1, 2021

Fried remembers the debate, featuring a then- High Times editor and a DEA agent, marking the first substantive cannabis conversation during her time at school. . Her cannabis stance is one of many reasons that Fried is considered a possible contender to DeSantis in 2022. Florida’s Ongoing Cannabis Reform Efforts.

Agriculture 52

Agriculture Policy THC Cannabis 52

Cannabis Law Report

JUNE 27, 2022

The Drug Enforcement Administration (DEA) said in a letter that marijuana seed that has a delta-9-THC concentration of not more than 0.3% Spain approves medical cannabis reform, pharmacy dispensing planned for end of 2022: [link]. CO: Two psychedelic-related initiatives may be on the 2022 ballot: [link]. INDUSTRY NEWS.

Seed-To-Sale 52

Seed-To-Sale Hemp Retail Treatment 52